Strong impact of pathological node‑negative on long‑term overall survival of patients with triple‑negative breast cancer receiving neoadjuvant chemotherapy

Nogi,Hiroko; Kamio,Makiko; Toriumi,Yasuo; Nagasaki,Eijiro; Suzuki,Masafumi; Takeyama,Hiroshi

doi:10.3892/mco.2021.2261

Strong impact of pathological node‑negative on long‑term overall survival of patients with triple‑negative breast cancer receiving neoadjuvant chemotherapy

Authors:
- Hiroko Nogi
- Makiko Kamio
- Yasuo Toriumi
- Eijiro Nagasaki
- Masafumi Suzuki
- Hiroshi Takeyama
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Jikei University School of Medicine, Tokyo 105‑8461, Japan, Department of Surgery, The Jikei University Kashiwa Hospital, Chiba 277‑8567, Japan, Department of Medical Oncology and Hematology, Jikei University School of Medicine, Tokyo 105‑8461, Japan, Department of Pathology, Jikei University School of Medicine, Tokyo 105‑8461, Japan
Published online on: March 13, 2021 https://doi.org/10.3892/mco.2021.2261
Article Number: 99
Copyright: © Nogi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) has a high pathological complete response (pCR) rate; however patients without a high pCR are reported to have a poor prognosis. The current study investigated the long‑term overall survival of patients with TNBC who received neoadjuvant chemotherapy (NAC) and analyzed various prognostic factors including basal marker and claudin expressions. Between November 2005 and March 2012, the current study retrospectively reviewed the records of 323 patients with breast cancer who received anthracycline followed by taxane as NAC at the Jikei University Hospital Basal marker and claudin expression was determined via immunohistochemistry. The median age of the patients was 53.0 years. Of the 323 patients, 26 (8%) achieved a pCR, including 13 patients (19.7%) with TNBC and 13 (5.1%) with non‑TNBC (P<0.001). Of the 66 patients with TNBC, 13 (19.7%) demonstrated recurrence and 8 (12.1%) died after a median follow‑up time of 111.5 months [10‑year disease‑free survival (DFS), 80.3%; 95% confidence interval (CI), 0.68‑0.88; 10‑year overall survival (OS), 84.8%; 95% CI, 0.72‑0.92]. Of the 257 patients with non‑TNBC, 45 (17.5%) patients demonstrated recurrence and 26 (10.1%) died (10‑year DFS, 82.1%; 95% CI, 0.76‑0.87; 10‑year OS, 88.6%; 95% CI, 0.83‑0.92). There was no statistical difference between the patients with and without TNBC. In the TNBC group, patients with pathological node‑negative status survived without distant recurrence. Additionally, negative lymphovascular infiltration was another favorable prognostic factor. Patients with TNBC who received NAC demonstrated comparably high prognoses to non‑TNBC patients. Overall, pathological node status after NAC had a strong impact on the prognosis of patients with TNBC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Hu K, Ding P, Wu Y, Tian W, Pan T and Zhang S: Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: An observational study based on the global burden of diseases. BMJ Open. 9(e028461)2019.PubMed/NCBI View Article : Google Scholar
3	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.PubMed/NCBI View Article : Google Scholar
4	Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S and Arpino G: Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 136:795–804. 2012.PubMed/NCBI View Article : Google Scholar
5	Bianchini G, Balko JM, Mayer IA, Sanders ME and Gianni L: Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 13:674–690. 2016.PubMed/NCBI View Article : Google Scholar
6	Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.PubMed/NCBI View Article : Google Scholar
7	Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008.PubMed/NCBI View Article : Google Scholar
8	Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, Fukushima H and Uchida K: EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep. 21:413–417. 2009.PubMed/NCBI
9	von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.PubMed/NCBI View Article : Google Scholar
10	Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, et al: Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the GeparSixto randomized clinical trial affiliations expand. JAMA Oncol. 3:1378–1385. 2017.PubMed/NCBI View Article : Google Scholar
11	Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, et al: Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: A landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol. 25:1128–1136. 2014.PubMed/NCBI View Article : Google Scholar
12	Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 384:164–172. 2014.PubMed/NCBI View Article : Google Scholar
13	Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M and Akiyama F: Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer. 22:486–495. 2015.PubMed/NCBI View Article : Google Scholar
14	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–572. 2000.PubMed/NCBI View Article : Google Scholar
15	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
16	Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8(R76)2007.PubMed/NCBI View Article : Google Scholar
17	Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12(R68)2010.PubMed/NCBI View Article : Google Scholar
18	Ding L, Lu Z, Lu Q and Chen YH: The claudin family of proteins in human malignancy: A clinical perspective. Cancer Manag Res. 5:367–375. 2013.PubMed/NCBI View Article : Google Scholar
19	Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011.PubMed/NCBI View Article : Google Scholar
20	Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, et al: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 19:5533–5540. 2013.PubMed/NCBI View Article : Google Scholar
21	Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA: Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One. 11(e0157368)2016.PubMed/NCBI View Article : Google Scholar
22	Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 376:2147–2159. 2017.PubMed/NCBI View Article : Google Scholar
23	Denkert C, Liedtke C, Tutt A and von Minckwitz G: Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 389:2430–2442. 2017.PubMed/NCBI View Article : Google Scholar
24	Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 379:2108–2121. 2018.PubMed/NCBI View Article : Google Scholar
25	Damaskos C, Garmpi A, Nikolettos K, Vavourakis M, Diamantis E, Patsouras A, Farmaki P, Nonni A, Dimitroulis D, Mantas D, et al: Triple-negative breast cancer: The progress of targeted therapies and future tendencies. Anticancer Res. 39:5285–5296. 2019.PubMed/NCBI View Article : Google Scholar
26	Nedeljković M and Damjanović A: Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 8(957)2019.PubMed/NCBI View Article : Google Scholar